An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy

Background C3 glomerulopathy (C3G) is associated with dysregulation of the alternative pathway of complement activation, and treatment options for C3G remain limited. Complement factor H (FH) is a potent regulator of the alternative pathway and might offer a solution, but the mass and complexity of FH makes generation of full-length FH far from trivial. We previously generated a mini-FH construct, with FH short consensus repeats 1-5 linked to repeats 18-20 (FH^{1-5^18-20}), that was effective in experimental C3G. However, the serum t_1/2 of FH^{1-5^18-20} was significantly shorter than that of serum-purified FH.

Methods We introduced the oligomerization domain of human FH-related protein 1 (denoted by R1-2) at the carboxy or amino terminus of human FH^{1-5^18-20} to generate two homodimeric mini-FH constructs (FH^{R1-2^1-5^18-20} and FH^{1-5^18-20^R1-2}, respectively) in Chinese hamster ovary cells and tested these constructs using binding, fluid-phase, and erythrocyte lysis assays, followed by experiments in FH-deficientCfh-/-mice.

Results FH^{R1-2^1-5^18-20} and FH^{1-5^18-20^R1-2} homodimerized in solution and displayed avid binding profiles on clustered C3b surfaces, particularly FH^{R1-2^1-5^18-20} Each construct was >10-fold more effective than FH at inhibiting cell surface complement activity in vitro and restricted glomerular basement membrane C3 deposition in vivo significantly better than FH or FH^{1-5^18-20} FH^{1-5^18-20^R1-2} had a C3 breakdown fragment binding profile similar to that of FH, a >5-fold increase in serum t_1/2 compared with that of FH^{1-5^18-20},and significantly better retention in the kidney than FH or FH^{1-5^18-20} 

Conclusions FH^{1-5^18-20^R1-2} may have utility as a treatment option for C3G or other complement-mediated diseases.